Roche announces collaboration with Ibex Medical Analytics to develop artificial intelligence-based digital pathology applications for better patient care
SANTA CLARA, Calif., Oct. 18, 2021 / PRNewswire / – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has entered into an agreement with Ibex Medical Analytics, a global leader in artificial intelligence (AI) -based on the diagnosis of cancer. Under the agreement, the companies will jointly develop an integrated image analysis workflow that enables pathologists to seamlessly access AI algorithms, information and decision support tools. Ibex using NAVIFY Digital Pathology, the cloud version of Roche’s uPath enterprise software. Collaborations with leading AI companies like Ibex are made possible through Roche’s open digital pathology environment, which allows pathologists to securely access third-party AI-based technology alongside the growing menu of Roche AI-based image analysis tools.
Ibex’s Galen ™ platform recently received breakthrough device designation from the United States Food and Drug Administration (FDA) and is CE marked in Europe for the detection of breast and prostate cancer in multiple streams of work. Through this alliance, customers using Roche Digital Pathology will have access to innovative tools from Ibex, such as algorithms that analyze prostate and breast biopsies, in addition to the AI tools already provided by Roche.
“With the addition of Ibex’s clinical-grade image analysis tools to our NAVIFY digital pathology menu, we can help pathologists and providers deliver value-based patient care by increasing their efficiency and their accuracy for a better quality cancer diagnosis, ”said Jill German, head of the Roche Diagnostics Pathology customer area.
The clinical-grade AI algorithms and digital workflows included in this extensive menu of tools will enable pathologists to deliver accurate, efficient and timely diagnoses to their patients and support them in cancer detection and classification, identification of important non-cancerous features, case reports and more.
“Digital pathology allows laboratories to introduce new innovative methods to improve the quality and efficiency of cancer diagnosis. Together with Roche, we look forward to transforming pathology by providing pathologists with powerful AI-based tools, ”said Joseph Mossel. , CEO and co-founder of Ibex Medical Analytics.
About Roche Digital Pathology
As a leading provider of pathology laboratory solutions, Roche offers an end-to-end digital pathology solution, from tissue staining to producing high-quality digital images that can be reliably assessed using automated clinical image analysis algorithms. We minimize the variables that can impact the analysis, and it is this end-to-end development that produces the quality results that healthcare providers and researchers can count on. With the acceleration of immunotherapy and the development of more complex tests, Roche is transferring these traditionally research-oriented tools into routine clinical practice and is committed to investing in and shaping the future of pathology.
Roche offers two deployment options for its uPath software: an on-premise solution and a cloud solution, marketed as NAVIFY Digital Pathology. The VENTANA DP 200 slide scanner and Roche uPath enterprise software are CE-IVD marked for in vitro diagnostic use and are available in the United States for Research Use Only (RUO). The image analysis algorithms developed by third parties and their use are the responsibility of the third party supplier.
Roche is a global pharmaceutical and diagnostics pioneer focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, along with growing capabilities in data-driven medical knowledge, help Roche deliver truly personalized healthcare. Roche works with partners in the healthcare industry to provide the best care for every person.
Roche is the world’s largest biotechnology company, with truly differentiated drugs in oncology, immunology, infectious diseases, ophthalmology and central nervous system diseases. Roche is also the world leader in in vitro diagnostics and tissue diagnostics for cancer, and a pioneer in the management of diabetes. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become a leading industry partner for medical knowledge.
Founded in 1896, Roche continues to research better ways to prevent, diagnose and treat disease and make a lasting contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty drugs developed by Roche are included in the World Health Organization’s Model Lists of Essential Medicines, including life-saving antibiotics, antimalarials and cancer drugs. In addition, for the twelfth year in a row, Roche has been recognized as one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices (DJSI).
The Roche group, headquartered in Basel, Switzerland, is active in more than 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and achieved sales of CHF 58.3 billion. Genentech, in the United States, is a full member of the Roche group. Roche is the majority shareholder of Chugai Pharmaceutical, in Japan. For more information, please visit www.roche.com.
For more information
Roche Tissue Diagnostics Communications
View original content to download multimedia:https://www.prnewswire.com/news-releases/roche-announces-collaboration-with-ibex-medical-analytics-to-develop-artificial-intelligence-based-digital-pathology-applications-for-improved-patient- care-301401567.html